Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

Original reporting
Published Oct 27, 2026, 11:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmonx (LUNG) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$LUNGBullishHigh
01

Why it matters

The earnings call provides the first public disclosure of Q3 2026 results, showing a return to growth and improved operating leverage, which can shift investor expectations.

02

Market read

First‑time earnings release with better‑than‑expected growth and margin guidance; likely to move LUNG stock and influence related respiratory‑device peers.

03

What to watch

China re‑entry may add volatility; trial enrollment timelines could delay revenue upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Pulmonx (LUNG) is a U.S. medical‑device company focused on endobronchial valves for COPD and lung volume reduction.

Company-level read

Ticker impact

$LUNGBullishHigh confidence
Context

Pulmonx reported Q3 2026 revenue of $22.8M, a 6% YoY increase and raised full‑year margin guidance to ~77%, indicating a turnaround.

Expected impact

likely upside as investors price in revenue growth and higher margins

Evidence & confidence

First‑time disclosure of quarterly results with better-than‑expected growth and margin expansion; market typically reacts positively to such earnings surprises.

Market effects

Positive signal for the medical device/respiratory therapy sector, may lift peers.

U.S. healthcare stocks could see modest gains.

Limited to niche respiratory‑device market; no broad macro effect.

Counterpoint

Margin guidance still modest; execution risk remains if international expansion stalls.

Key entities

  • Glendon E. French

    CEO of Pulmonx, presented the earnings call.

  • Derrick Sung

    CFO/COO, detailed financial results.

Related articles

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGMed

Pulmonx Reports Third Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi